HIV-1 integrase: A target for new AIDS chemotherapeutics

Current Topics in Medicinal Chemistry

Volumn 4, Issue 9, 2004, Pages 979-990

  Anthony, Neville J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; 8 HYDROXY 1,6 NAPHTHYRIDIN 7 CARBOXAMIDE DERIVATIVE; 8 HYDROXY 1,6 NAPHTHYRIDINE DERIVATIVE; CICHORIC ACID; INTEGRASE INHIBITOR; L 708906; L 870812; MERCAPTOSALICYLHYDRAZINE; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NAPHTHYRIDINE DERIVATIVE; NELFINAVIR; NEVIRAPINE; NUCLEOTIDYLTRANSFERASE INHIBITOR; PROTEINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; V 165; VIRUS DNA; VIRUS ENZYME; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CATALYSIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; METABOLISM; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2942527726     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388448     Document Type: Review

References (75)

1. Gayle, H.D. The Global Epidemiology of HIV/AIDS December 3, 2002. Nobelforum, Karolinska Institute, Sweden.
2. Hogberg, M., Morrison, I. HIV-1 non-nucleoside reverse transcriptase inhibitors. Exp. Opin. Ther.Patents. 2000, 10, 1189-1199.
3. Jonckheere, H., Anne, J., De Clercq, E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 2000, 20, 129-154.
4. Lebon, F., Ledecq, M.Approaches to the design of effective HIV-1 protease inhibitors. Curr. Med. Chem. 2000, 7, 455-477.
5. Kilby, J. M., Hopkins, S., Vendetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M. R., Nowak, M. A., Shaw, G. M., Saag, M. S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 1998, 4 1302.
6. Esposito, D., Craigie, R. HIV Integrase structure and function. Advances in Virus Research 1999, 52, 319-333;
7. Asante-Appiah, E., Skalka, A. M. HIV-1 integrase: structural organization, conformational changes, and catalysis. Advances in Virus Res. 1999, 52, 351-369.
8. Nair, V. HIV Integrase as a Target for Antiviral Chemotherapy. Rev. Med. Virol. 2002, 12, 179
9. Pani, A., Marongiu, M.E. Anti HIV-1 Integrase Drugs: How far from the shelf? Curr. Pharm. Design, 2000, 6, 569.
10. Young, S. D. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Current Opinion in Drug Discovery & Development 2001, 4, 402.
11. Tarrago-Litvak, L., Andreola, M.L., Fournier, M., Nevinsky, G.A., Parissi, V., de Soultrait, V.R., Litvak, S. Inhibitors of HIV-1 Reverse Transcriptase and Integrase: Classical and Emerging Therapeutical Approaches. Curr. Pharm. Design 2002, 8, 595
12. Ramratnam, B., Mittler, J.E., Zhang, L., Boden, D, Hurley, A., Fang, F., Macken, C.A., Perelson, A. S., Markowitz, M., Ho, D.D. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 2000, 6, 82.
13. Young, S.D. Recent advances in the chemotherapy of HIV. Annual Reports in Medicinal Chemistry 2003, 38, 173.
14. DeClercq. New developments in anti-HIV chemotherapy. Biochim. et Biophys. Act. 2002, 1587, 258.
15. Gulick, R.M. New antiretroviral drugs. Clin. Microbiol. Infect 2003, 9, 186
16. Palella, F.J., Delaney, K.M., Moorman, A.C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., Holmberg, S. D. and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 338, 853.
17. Lucas, G.M., Chaisson, R. E. and Moore, R.D. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 1999, 131, 81-87.
18. Yerly, S., Kaiser, L., Race, E., Bru, J. P., Clavel, F. and Perrin, L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354, 729-733.
19. Furtado, M.R., Callaway, D.S., Phair, J. P., Kunstman, K. J., Stanton, J. L., Macken, C. A., Perelson, A. S. and Wolinsky, S. M. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 1999, 340, 1614-1622.
20. Schroder,A.R.W., Shinn, P., Chen, C., Berry, C., Ecker, J.R., Bushman,F. HIV-1 Integration in the human Genome favors active genes and local hotspots. Cell, 2002, 110, 521.
21. Stevens, S.W., Griffith J.D. Sequence analysis of the human DNA flanking sites of human immunodeficiency virus type 1 integration. J. Virol. 1996, 70, 6459.
22. Pruss, D., Bushman, F.D., Wolffe, A.P. Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core. Proc. Natl. Acad., Sci. USA, 1994, 91, 5913.
23. Bor, Y.C., Miller, M.D., Bushman, F.D., Orgel, L.E. Target-sequence preferences of HIV-1 integration complexes in vitro. Virology 1996, 222, 283.
24. Goodarzi, G., Parsley, M., Felock, P., Witmer, M., Hazuda, D., Brackmann, K., Grandgenett, D. Efficiency and fidelity of full-site integration reactions using recombinant simian immunodeficiency virus integrase. J. Virol. 1999, 73, 8104.
25. Wu, X., Liu, H., Xiao, H., Conway, J. A., Hehl, E., Kalpana, G. V., Prasad, V., Kappes, J.C. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J. Virol. 1999, 73, 2126.
26. Lee, M. S., Craigie, R. A previously unidentified host protein protects retroviral DNA from autointegration. Proc. Natl. Acad. Sci.USA. 1998, 95, 1528.
27. Chen, H., Engelman, A. The barrier-to-autointegration protein is a host protein factor for HIV type 1 integration. Proc. Natl. Acad. Sci. USA 1998, 95,15270.
28. Cai, M., Huang, Y., Zheng, R., Wei, S. Q., Ghirlando, R., Lee, M. S., Craigie, R., Gronenborn, A. M., Clore, G. M. Solution structure of the cellular factor BAF responsible for protecting retroviral DNA from auto integration. Nat. Struct. Biol. 1998, 5, 903.
29. Umland, T. C., Wei, S. Q., Craige, R., Davies, D. R. Structural Basis of DNA Bridging by Barrier-to-Autointegration Factor. Biochemistry. 2000, 39, 9130.
30. Yung, E., Sorin, M., Pal, A., Craig, E., Morozov, A., Delattre, O., Kappes, J., Ott, D.,.Kalpana, G.V. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nature Med. 2001, 7, 920.
31. Landau, N. R. A cellular cofactor in HIV-1 assembly: IN11 is also an 'outtie' Trends in Pharm. Sci. 2002, 23, 252.
32. Cherepanov, P., Maertens, G., Proost, P., Devereese, B., Beeumen, J.V., Engelborghs, Y., De Clercq, E., Debyser, Z., HIV-1 integrase forms stable tetramers and associate with LEDGF/p75 protein in human cells. J. Biol. Chem. 2003, 278, 372.
33. Zheng, R., Jenkins, T.M., Craige, R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization and enhances catalytic activity. Proc. Natl. Acad. Sci USA 1996, 93, 13659.
34. Cai, M., Zheng, R., Caffrey, M., Craigee, R. Clore, G. M., Gronenborn, A.M. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 1997, 4, 567.
35. Heuer, T.S., Brown, P.O. Photo-Crosslinking Studies Suggest a Model for the Architecture of an Active Human Immunodeficiency Virus Type 1 Integrase-DNA Complex. Biochemistry 1998, 37, 6667.
36. Kulkosky, J., Jones, K. S., Katz, R. A., Mack, J.P., Skalka A. M., Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol. Cell Biol. 1992, 12, 2331.
37. Leavitt, A.D., Shiue, L., Vaarmus, H. E. Site directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. J. Biol. Chem. 1993, 268, 2113.
38. Eijkelenboom, A.P., Lutzke, R.A., Boelens, R., Plasterk, R.H., Kaptein, R., Hard, K. The DNA-binding domain of HIV-1 integrase has an SH3-like fold. Nat Struct. Biol. 1995, 2, 807.
39. Lutzke, R.A., Plasterk, R.A. Structure-bascd mutational analysis of the C-terminal DNA-binding domain of human immunodeficiency virus type 1 integrase: critical residues for protein oligomerization and DNA binding. J. Virol. 1998, 72, 4841.
40. Engelman, A., Bushman, F.D., Craige, R. Identification of discrete function domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 1993, 12, 3269.
41. Chen, J.C., Krucinskji, J., Miercke, L.J., Finer-Moore, J.S., Tang, A.H. Leavitt, A.D., Stroud, R.M. Crystal structure of the HIV-1 integrase catalytic core and c-terminal domains: A model for viral DNA binding. Proc. Natl. Acad. Sci. USA. 2000, 97, 8233.
42. Dyda, F., Hickman, A.B., Jenkins, T., Engleman, A., Craigie, R., Davies, D. crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases. Science 1994, 266, 1981.
43. Wang, J-Y., Ling, H., Yang, W., Craigie, R. Structure of a two domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 2001, 20, 7333.
44. Goldgur, Y., Craigie, R., Cohen, G.H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo,T., Murai, H., Davies, D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 1999, 96, 13040.
45. Sotriffer, C.A., Ni, H., McCammon, J.A. HIV-1 integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J. Am. Chem. Soc. 2000, 122, 6136.
46. Ni, H., Sotriffer, C. A., McCammon, Ordered water and ligand mobility in HIV-1 integrase-5CITEP complex: A molecular dynamics study. J. Med. Chem. 44, 3043, 2001.
47. Espeseth, A.Z., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N,J., Egbertson, M., Melamed, J.Y., Young, S., Hamill, T., Cole, J.L., Hazuda, D.J. HIV-1inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA. 2000, 97, 11244.
48. Perryman, A. L., McCammon, J.A. autodocking dinucleotides to the HIV-1 integrase core domain: exploring possible binding sites for viral and genomic DNA. J. Med. Chem. 2002, 45, 5624.
49. Dirac, A. M., Kjems, J., Mapping DNA-binding sites of HIV-1 integrase by protein fingerprinting. Eur. J. Biochem. 2001, 268, 743.
50. Gerton, J.L., Herschlag, D., Brown, P.O., Stereospecificity of reactions catalyzed by HIV-1 interase. J. Biol. Chem. 1999, 274, 33480.
51. Bernardi, F., Bottoni, A., DeVivo,M. Garavelli, M., Keseru, G., and Naray-Szabo, G. A hypothetical mechanism for HIV-1 integrase catalytic action: DFT modelling of a bio-mimetic environment. Chem. Phys. Lett. 2002, 362, 1.
52. Pommier, Y., Marchand, C., Neamati, N. Retroviral integrase inhibitors year 2000 update and perspectives. Antiviral Res. 2000, 47, 139.
53. Pluymers, W., De Clercq, E., Debyser, Z. Curr. Drug Targets Infect. Disorders. 2001, 1, 133.
54. Chen, I., Neamati, N., MacKerell, A.D. Structure-based inhibitor design targeting HIV-1 integrase. Curr.Drug Targets Infect. Disorders. 2002, 2, 217.
55. Pais, C.G., Burke, Jr, T.R. Novel aryl diketone containing inhibitors of HIV-1 integrase. Drugs of the future. 2002, 27, 1101.
56. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: a 10 year saga. Expert Opin. Ther. Patents. 2002, 12, 709.
57. Hazuda, D. J., Felock, P., Witmar, M., Wolfe, A.; Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L, Schleif, W., Blau, C., Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646.
58. Reinke, R., Lee, D.J., Robinson, W.E. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor 1-731,988, a diketo acid. Antimicrob. Agents. Chemother. 2002, 46, 3301.
59. Pluymers, W., Pais, G. Van Maele, B., Pannecouque, C. Fikkert V., Burke, T.R., De Clercq, E., Witvrouw, M., Neamati, N., Debyser, Z. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicro. Agents Chemother. 2002, 46, 3292.
60. Melek, M., Jones, J. M., O'Dea, M. H., Pais, G., Burke, T. R., Pommier, Y., Neamati, N., Gellert, M. Effect of HIV integrase inhibitors on the RAG1/2 recombinase Proc. Natl. Acad. Sci. USA. 2002, 1,137.
61. Marchand, C., Zhang, X., Pais, G.C.G., Cowansage, K., Meamati, N., Burke, T.R., Pommier, Y. Structural determinants for HIV-1 integrase inhibition by β-diketo acids J. Biol. Chem. 2002, 277, 12596.
62. Grobler, J.A., Stillmock, K., Hu, B., Wilmer, M., Felock, P., Espeseth, A.S., Wolfe, A., Bourgeois, Melamed, J., Wai, J.S., Young, S.D., Vacca, J., Hazuda, D.J. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 2002, 99, 6661.
63. Cowan, J.A. Metal activation of enzymes in nucleic acid biochemistry. Chem. Rev. 1998, 98, 1067.
64. Wai, J.S., Egbertson, M.S., Payne, L.S., Fisher, T.E., Embrey,M.W., Tran, L.O., Malamed, J.Y., Langford, H. M., Guare, J.P., Zhuang,L., Grey,V.E., Vacca, J.P., Holloway, M.K., Naylor-Olsen, A.M., Hazuda, D.J., Felock, P.J., Wolfe, A.L., Stillmock, K.A., Schleif, W.A., Gabryelski, L.J., Young,S.D. 4-Aryl-2,4,dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem. 2000, 43, 4923.
65. Yoshinaga, T., Fujishita, T., Fujiwara, T. 2002, 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA.
66. Leese, P., Lippert, C., Russell, T., Fujiwara, T. S-1360: A new HIV integrase inhibitor. Repeat dose pharmacokinetics and safety in healthy volunteers following oral administration. XIV International Aids Conference, 2002 Barcelona, Spain.
67. Zhuang, L., Wai, J. S., Embrey, M. W., Fisher, T. E., Egbertson, M. S., Payne, L. S., Guare J. P. Jr., Vacca, J. P., Hazuda, D. J., Felock, P. J., Wolfe, A. L., Stillmock, K. A., Witmer, M. V., Moyer, G., Schleif, W. A., Gabryelski, L. J., Leonard, Y. M., Lynch, J. J. Jr., Michelson, S. R. and Young. S. D. Design and Synthesis of 8-Hydroxy-[1,6] Naphthyridines as Novel Inhibitors of HIV-1 Integrase in Vitro and in Infected Cells. J. Med. Chem. 2003, 46, 453.
68. Anthony, N.J, Gomez, R.P., Young, S.D., Egbertson, M., Wai, J.S., Zhang, L., Embrey, M., Tran, L., Melamed, J., Langford, H.M., Guare, J.P., Fisher, T.E., Jolly, S.M., Kuo, M.S., Perlow, D., Bennett, J.J., Funk, T.W. PCT Patent Pppl. 2002. WO0230931-A2.
69. Hazuda, D.J. Antiviral. Ther. 2002, 7, S3
70. Young, S.D., 2002. XIV Intl. AIDS Conf. Barcelona, Spain, Abs. LpPeA9007.
71. Young, S.D., Antiviral. Ther. 2002, 7, S4.
72. Pannecouque, C., Pluymers, W., Van Maele, B., Tetz, V., Cherepanov, P., De Clercq, E., Witvrouw, M. and Debyser, Z. New class of HIV integrase inhibitors that block viral replication in cell culture Curr. Biol. 2002, 12, 1169.
73. Neamati, N., Lin, Z., Karki, R. C., Orr, A., Cowansage, K., Strumberg, D., Pais, G. C. G., Voight, J. H., Nicklaus, M. C., Winslow, H. E., Zhao, H., Turpin, J. A., Yi, J., Skalka, A. M., Burke, T.R., Pommier, Y. Metal dependent inhibition of HIV-1 integrase. J. Med. Chem. 2002, 45, 5661.
74. Pluymers, W., Neamati, N., Pannecouque, C., Fikkert, V., Marchand,C., Burke Jr., T.R., Pommier,Y., Schols, D., DeClercq,E., Debyser, Z., Witvrouw,M. Viral entry as the primary target for the anti HIV activity of chicoric acid and its tetra-acetyl esters Mol. Pharmacol. 2000, 58, 641.
75. Reinke,R.A., King, P.J., Victoria, J.G., McDougall, B.R., Ma, G., Mao, Y., Reinecke, M.G., Robinson Jr, W.E. Dicaffeoyltartaric acid analogs inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations. J. Med. Chem. 2002, 45, 3669.